FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
September 17, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 29, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
August 20, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
Positive Results from Cohort 5 of Phase 1b TrialCompany Intends to Initiate a Sixth Cohort and Transition Ongoing Phase 2 Trial to a Fractionated Dose MADISON, Wis., Aug. 20, 2018 (GLOBE...
Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma
August 13, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update
August 10, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB)(“Cellectar or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development...
Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate
August 01, 2018 08:30 ET
|
Cellectar Biosciences, Inc.; Orano Med
MADISON, Wis. and COURBEVOIE, France, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
July 31, 2018 16:05 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., July 31, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering
July 27, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., July 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB) (“Cellectar” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery, development...
Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
July 18, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., July 18, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study
July 17, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., July 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...